[Federal Register Volume 91, Number 139 (Wednesday, July 22, 2026)] [Notices] [Pages 46123-46125] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2026-14707] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2026-N-1849] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Notifications Submission AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. DATES: Submit written comments (including recommendations) on the collection of information by August 21, 2026. ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to https://www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting ``Currently under Review--Open for Public Comments'' or by using the search function. [Note to drafter: choose one of these statements. If there is a complete (8 digit) OMB control number, state: ``The OMB control number for this information collection is 0910-0120. Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Amber Barrett, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-8867, [email protected]. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. [[Page 46124]] Premarket Notifications Submission 510(k),--21 CFR, Part 807 Subpart E OMB Control Number 0910-0120--Extension This information collection helps support implementation of statutory provisions that govern premarket clearance of devices. Section 510(k) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360(k)) and implementing regulations in part 807, subpart E (21 CFR part 807, subpart E), establish premarket notification procedures. Persons who intend to market a medical device, for which a premarket approval application (PMA) is not required, must submit a premarket notification to FDA, unless the device is exempt from 510(k) requirements and does not exceed the limitations of exemptions of the device classification regulations, at least 90 days before proposing to begin the introduction, or delivery for introduction into interstate commerce, for commercial distribution of a device intended for human use. Based on the information provided in the notification, FDA must determine whether the new device is substantially equivalent to a legally marketed device. If a device is determined to be not substantially equivalent to a legally marketed device, it must have an approved PMA, product development protocol, humanitarian device exemption (HDE), request for an evaluation of automatic class III designation (De Novo request), or be reclassified into class I or class II before being marketed. The information collection also helps support section 510(l) of the FD&C Act, which provides for exemption from premarket notification. The following instruments are included in the information collection:Form FDA 3514, ``CDRH Premarket Review Submission Cover Sheet'' Form FDA 3881, ``Indications for Use'' Voluntary eSTAR Program Interactive PDF Form and instructional web page Form FDA 4062, ``Electronic Submission Template and Resource (eSTAR)'' (for non-In Vitro Diagnostic (IVD) 510(k) submissions) Form FDA 4078, ``Electronic Submission Template and Resource (eSTAR)'' (for In Vitro Diagnostic (IVD) 510(k) submissions) We are revising the information collection to include Form FDA 3674, ``Certification of Compliance, Under 42 U.S.C., 282(j)(5)(B), with Requirements of ClinicalTrials.gov. '' Under applicable authorities, applications under sections 505, 515, or 520(m) of the FD&C Act (21 U.S.C. 355, 360e, or 360j(m)), or under section 351 of the Public Health Service Act (42 U.S.C. 262), or submission of a report under section 510(k) of the FD&C Act, must be accompanied by a certification. Where available, such certification must include the appropriate National Clinical Trial numbers. The information collection also includes an ``Acceptance Checklist.'' As discussed in the guidance document ``Refuse to Accept Policy for 510(k)s'' (April 2022), available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/refuse-accept-policy-510ks, we believe the checklist can be a helpful resource for 510(k) submitters and may simplify preparation of the 510(k). Similarly, the guidance document ``Recognition and Withdrawal of Voluntary Consensus Standards'' (September 2020), available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recognition-and-withdrawal-voluntary-consensus-standards, communicates procedures followed by the Center for Devices and Radiological Health (CDRH) when requests for recognition of a voluntary consensus standard for medical products are received. The guidance document outlines principles for recognizing a standard wholly, partly, or not at all, as well as reasons and rationales for withdrawing a standard. Section 514 of the FD&C Act (21 U.S.C. 360d) allows FDA to recognize consensus standards developed by international and national organizations for use in satisfying portions of device premarket review submissions, including premarket notifications or other requirements. We publish and update the list of recognized standards regularly at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Standards/ucm123792.htm. As instructed in the guidance document, any interested party may submit a request for recognition of a standard by mail directed to the CDRH Standards Program (i.e., paper copy) or electronically via email. For efficiency of Agency operations, we are also revising the information to include activities associated with section 520(b) of the FD&C Act, governing custom devices. Regulations in 21 CFR 812.3 define a custom device and implementing regulations in 21 CFR 807.85 provide for exemption from premarket notification. Section 520(b) of the FD&C Act also provides for the issuance of guidance. The guidance document entitled, ``Custom Device Exemption'' (September 2014), and available for download at https://www.fda.gov/media/89897/download, explains how FDA interprets provisions in section 520(b)(2)(B) of the FD&C Act, describes what information should be submitted in a Custom Device Annual Report (``annual report''), and provides recommendations on how to submit an annual report for devices distributed under the custom device exemption. Finally, we discuss the guidance document entitled, ``Transition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency,'' announced in the Federal Register of March 27, 2023 (88 FR 18153), which describes a phased approach intended to help avoid disruption in device supply and help facilitate compliance with applicable legal requirements. The recommendations discussed in the guidance document result in the one-time collection of information intended to ensure an orderly and transparent transition from temporary policies established during the COVID-19 public health emergency to normal operations. Because the information collection recommendations apply to specific medical devices already in distribution, we believe the information discussed is appropriately characterized as nonstandardized followup designed to clarify responses to approved collections of information (i.e., plans for compliance with applicable requirements unique to that distributed device). We therefore believe the activity constitutes the collection of non-identical and/or followup information, as defined under 5 CFR 1320.3. At the same time, we expect some degree of fluctuation in future submissions under part 807, subpart E, as a result of implementation of the medical device transition plan. In the Federal Register of March 19, 2026 (91 FR 13310), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received. FDA estimates the burden of this collection of information as follows: [[Page 46125]] Table 1--Estimated Annual Reporting Burden -------------------------------------------------------------------------------------------------------------------------------------------------------- Number of Activity and 21 CFR Part/Section Form No. Number of responses per Total annual Average burden per Total hours respondents respondent responses response -------------------------------------------------------------------------------------------------------------------------------------------------------- 21 CFR Part 807, Subpart E, PREMARKET NOTIFICATION PROCEDURES -------------------------------------------------------------------------------------------------------------------------------------------------------- 510(k) submission (807 subpart E)..... FDA 3881................. 3,800 1 3,800 79.25................... 301,150 Summary cover sheet (807.87).......... FDA 3514................. 1,906 1 1,906 0.5 (30 minutes)........ 953 Status request (807.90(a)(3))......... ......................... 1 1 1 0.25 (15 minutes)....... 1 510(k) summary (807.92)............... ......................... 2,742 1 2,742 4....................... 10,968 510(k) statement (807.93)............. ......................... 130 1 130 0.08 (5 minutes)........ 10 510(k) submission (807 subpart E)-- FDA 4062, FDA 4078....... 3,800 1 3,800 40...................... 152,000 using eSTAR format. -------------------------------------------------------------------------------------------------------------------------------------------------------- Guidance Document Recommendations: -------------------------------------------------------------------------------------------------------------------------------------------------------- Request for recognition of a voluntary ......................... 5 1 5 1....................... 5 consensus standard. Annual reporting for custom devices ......................... 31 1 31 40...................... 1,240 under 520(b) of the FD&C Act. -------------------------------------------------------------------------------------------------------------------------------------------------------- 42 CFR part 11, Clinical Trials Registration and Results Information Submission, subparts D and E; and FDA Guidance ``Form FDA 3674--Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions'' -------------------------------------------------------------------------------------------------------------------------------------------------------- Certification to accompany 510(k) FDA 3674................. 3,800 1 3,800 0.75 (45 minutes)....... 2,850 submissions. -------------------------------------------------------------------------------------------------------------------------------------------------------- Electronic Submission Template and Resource (eSTAR) -------------------------------------------------------------------------------------------------------------------------------------------------------- eSTAR setup--one-time burden.......... ......................... 80 1 80 0.08 (5 minutes)........ 6 ----------------------------------------------------------------------------------------------------------------- Total............................. ......................... .............. .............. 16,295 ........................ 469,183 -------------------------------------------------------------------------------------------------------------------------------------------------------- The information collection reflects program changes and adjustments. We have also made nominal adjustments on individual provisions to reflect expected fluctuations in submissions. Cumulatively these actions result in an overall increase of 145,804 hours and a corresponding increase of 3,625 responses annually. The increase was attributed to the 510(k) submissions increase from 100 to 3,800. Grace R. Graham, Deputy Commissioner for Policy, Legislation, and International Affairs. [FR Doc. 2026-14707 Filed 7-21-26; 8:45 am] BILLING CODE 4164-01-P